Key result
BGP-15 exerts direct and indirect negative inotropic effects on human myocardium with lower potency than propranolol.
Why the study?
Because BGP-15 shares structural similarity with propranolol, it was investigated whether BGP-15 also exerts direct or indirect effects on human cardiac contractility.
Does BGP-15 exert a negative inotropic effect on isolated human right atrial myocardium compared to propranolol?
Does BGP-15 exert a negative inotropic effect on isolated human right atrial myocardium compared to propranolol?
BGP-15 exerts a negative inotropic effect on human atrial myocardium, with enhanced effects in tissue from diabetic patients or those with high isoproterenol sensitivity, mediated by pathways partially distinct from propranolol.
BGP-15 may reduce atrial contractility ex vivo, especially in diabetic tissue; leaves open in vivo hemodynamic effects and clinical relevance.
Cardiovascular morbidity and mortality carry great socioeconomic burden worldwide that mandates the development of new, efficacious therapeutic agents with limited adverse effects. O-(3-piperidino-2-hydroxy-1-propyl) nicotinic acid amidoxime (BGP-15) is a known, well-tolerable drug candidate that exerts beneficial effects in several disease models. As BGP-15 has a significant structural similarity with propranolol, it arose that BGP-15 might also have a direct effect on the heart. Thus, in the present work, we investigated the effect of BGP-15 and propranolol on the contractility of isolated, paced, human right atrial samples (obtained from patients undergone open-heart surgery), with or without previous isoproterenol (ISO) stimulation (evoking an indirect or direct effect, respectively). We found that both BGP-15 and propranolol exerted direct as well as indirect negative inotropic effects on the atrial myocardium, reaching similar maximal response. However, BGP-15 had considerably smaller potency than propranolol regarding both types of negative inotropy. In addition, BGP-15, in contrast to propranolol, had a significantly greater indirect negative inotropic effect on samples exhibiting strong response to ISO. Moreover, the indirect negative inotropic effect of BGP-15 was significantly greater on samples derived from diabetic patients than on samples obtained from non-diabetic ones. Our results suggest that the enhanced ISO sensitivity is associated with the diabetic state, and BGP-15 exerts greater negative inotropic effect on the human atrial myocardium in both conditions (as compared to the atrial tissue that is not ISO oversensitive and/or diabetic). Additionally, the negative inotropic effects of BGP-15 and propranolol seem to be mediated by in part different molecular pathways in the atrial myocardium.
No takes yet. Share an insight, caveat, or question.
Lampé et al. (2020) studied Patients undergoing open-heart surgery (n=30). BGP-15 vs. Propranolol was evaluated on Direct and indirect negative inotropic effect (contractile force) on isolated right atrial samples. BGP-15 exerts both direct and indirect negative inotropic effects on ex vivo human right atrial myocardium with a similar maximal response but considerably lower potency compared to propranolol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: